Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review by Lu Wang, Shidi Wen, Wenjia Zhu, Zhiyang Zhang, Yuejuan Cheng

Subjects: “…antibody-drug conjugate…”
Get full text

Six events that shaped antibody approvals in oncology by Suman Paul, Suman Paul, Shibin Zhou, Shibin Zhou

Subjects: Get full text

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer by Shuailei Dong, Chen Wei, Xueting Wang, Xinyi Yang, Wei Shen, Shuyi Li, Jiye Xu, Yijie Ma, Liangyu Bie, Wenyue Yu, Ning Li

Subjects: Get full text

Production of antibodies and antibody fragments containing non-natural amino acids in Escherichia coli by Jacquelyn Blake-Hedges, Dan Groff, Wilson Foo, Jeffrey Hanson, Elenor Castillo, Miao Wen, Diana Cheung, Mary Rose Masikat, Jian Lu, Young Park, Nina Abi Carlos, Hans Usman, Kevin Fong, Abigail Yu, Sihong Zhou, Joyce Kwong, Cuong Tran, Xiaofan Li, Dawei Yuan, Trevor Hallam, Gang Yin

Subjects: “…Antibody–drug conjugate…”
Get full text

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer by Xiaojie Chu, Seungmin Shin, Du-San Baek, Liyong Zhang, Alex Conard, Megan Shi, Ye-Jin Kim, Cynthia Adams, Maggie Hines, Xianglei Liu, Chuan Chen, Zehua Sun, Dontcho V. Jelev, John W. Mellors, Dimiter S. Dimitrov, Wei Li

Subjects: “…Antibody drug conjugate…”
Get full text